Navigation Links
BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
Date:11/12/2007

of attack in many MS patients. This is accomplished by the I.V. injection of MBP8298 every six months.

Phase II and long-term follow-up treatment of MS patients with MBP8298, recently published in the European Journal of Neurology showed that MBP8298 safely delayed the median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.

MBP8298 is being developed in three late-stage clinical trials:

- MAESTRO-01: A pivotal phase III trial in Canada and Western Europe

evaluating MBP8298 for the treatment of secondary progressive

multiple sclerosis (SPMS). The trial is a randomized, double-blind

study and is fully recruited with 611 patients.

- MAESTRO-03: A pivotal phase III U.S. trial evaluating MBP8298 for the

treatment of SPMS. The trial is a randomized, double-blind study

enrolling approximately 510 patients.

- MINDSET-01: A phase II trial evaluating MBP8298 for the treatment of

relapsing remitting multiple sclerosis (RRMS). The trial is a

randomized, double-blind study and is fully recruited with 218

patients.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Com
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Globus Medical Announces Record 2nd Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 6, 2015  Endo International plc (NASDAQ: ENDP ) ... President and CEO, will present a corporate overview at the ... on Wednesday, May 20, 2015 at 11:00 a.m. ... for the event will be available on the Company,s website ... the link to the event. Participants should allow approximately 10 ...
(Date:5/6/2015)... -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company ... announced that Linda Powers , NW Bio CEO, will present ... for solid tumor cancers and the Company,s multiple clinical programs ... , , , DATE: , , , Thursday, May ... , 12:15 PM EDT , , , , LINK: ...
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine company ... grown under simulated embryonic conditions, will present new ... melanoma during the 2015 Society of Investigative Dermatology ... in Atlanta, GA. , Histogen has previously shown ... with anti-oncologic properties, with potential benefit in the ...
(Date:5/5/2015)... May 5, 2015  Blueprint Medicines (NASDAQ: ... initial public offering of 9,367,708 shares of common ... per share, including shares of common stock issued ... their option to purchase additional shares. The gross ... Medicines were approximately $168.6 million, before underwriting discounts and ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... Vermillion, Inc. (NASDAQ: VRML ), a molecular ... Trademark Office (USPTO) has issued a notice of allowance for ... claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that ... "This will be our third patent for biomarkers that ...
... in hospitals is increasing. Bacteria acquire resistance to antibiotics ... genes, either from the surrounding environment or from other ... research (University of Lisbon) and the Instituto Gulbenkian de ... resistance are playing out in the bacterium Escherichia ...
... signals, for the first time, to assist in braking, ... to the thousands of car accidents that are caused ... technique that attaches electrodes to the scalp , the ... traffic sensors, could detect a driver,s intention to break ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 3Bacterial resistance to antibiotics: The more they resist, the more they divide 2Put the brakes on using your brain power 2
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... German . , Berlin, 2 September 2009 - ... ecosystems - from forests and mangroves to wetlands and river ... change and climate-proofing vulnerable economies. This is among the ... Economics of Ecosystems and Biodiversity (TEEB), a project launched by ...
... JACKSONVILLE, Fla. In a biological rendition of fiction,s ... the Mayo Clinic campus in Florida and Harvard Medical School ... development can actually spur the spread of tumors. ... Molecular and Cellular Biology , found that FOXO3a, a transcription ...
... that comes to mind when people think of Alzheimer,s disease, ... and France, this might change. That,s because these researchers have ... might be the key that unlocks an entirely new class ... report published online in The FASEB Journal ( ...
Cached Biology News:Time to tap climate change-combating potential of the world's ecosystems 2Time to tap climate change-combating potential of the world's ecosystems 3Time to tap climate change-combating potential of the world's ecosystems 4Time to tap climate change-combating potential of the world's ecosystems 5Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side 2Scientists begin to untangle root cause of Alzheimer's disease 2
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Biology Products: